The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

The present invention provides a Solanum lycopersicum seed oil freeze-dried powder with whitening efficacy, a composition, and a preparation method and application thereof. The Solanum lycopersicum seed oil freeze-dried powder has significant whitening efficacy. If the Solanum lycopersicum seed oil freeze-dried powder is used in combination with a lemon verbena extract with a dose ratio of 3:1, the whitening effect is synergistic with the lemon verbena extract. The Solanum lycopersicum seed oil freeze-dried powder is an ideal raw material for preparing a whitening drug and a cosmetic.

A refillable unit dose package for frozen cosmetic or personal care products that can provide a chilling effect during application. The main components of the package are a reservoir and an applicator. The applicator comprises a handle and an applicator head depending from the handle. In use, a product in the reservoir is frozen, which causes the product to bond to the applicator head. The handle is used to lift the frozen product out of the reservoir, and draw the frozen product over the skin. As it melts from the heat of the skin, the product can be spread on the skin. The reservoir is refillable by a consumer.

The present invention provides a composition for lipolysis, for example a pharmaceutical composition for preventing or treating obesity including localized fat deposits (LFD), comprising certain phosphocholine derivatives or pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention shows an excellent lipolytic activity as well as a uniform lipolytic activity. And also, the pharmaceutical composition of the present invention can minimize side effects such as inflammation, tissue necrosis, etc., at the administered site. In addition, the pharmaceutical composition of the present invention has excellent storage stability.

A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.

The present invention relates to a composition for the protection against solar radiation, consisting of an organic matrix, preferably a gelatin, and hydroxyapatite nanoparticles modified by the substitution of part of the phosphorus with titanium, and part of the calcium with iron.

One or more techniques, systems and articles of manufacture are described for a product that is dried and can subsequently be rehydrated to produce a cosmetic or pharmaceutical. A molded and dried preparation has water weight of greater than zero and less than 50 percent. The dried preparation is form by drying a liquid preparation that contains a base material, an active ingredient and an inactive ingredient. The molded and dried preparation is configured to be rehydrated with water or another aqueous based solution or emulsion. The preparation may rapidly dissolve with the solvent to obtain a ready-to-use liquid or semi-solid product for topical cosmetic or pharmaceutical application.

Provided herein are growth factor concentrates, the method of preparing the growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates include decapsulated growth factors derived from platelet rich plasma.

Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles. This material has applications in biomedicine due to its biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it may be used in toothpastes, mouthwashes, chewing gums, gels and fluoride varnishes as a remineralising agent of dentine and enamel. It is based on two solutions formed by calcium chloride and sodium citrate on the one hand, and by sodium monohydrogenophosphate and sodium carbonate with a fluoride compound on the other, which are mixed at room temperature. The process is eco-efficient and eco-friendly, as it does not leave any acid residue; it consists of a single stage and it is the first time that an amorphous calcium phosphate coated with citrate and doped with fluoride, which enhances its remineralising action, is obtained.

The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.